ATPS-28COMBINED DRUG SCREENING AND PHOSPHOPROTEOMICS IDENTIFIES CANDIDATE BRAIN TUMOR THERAPEUTICS IN PRIMARY HUMAN BRAIN TUMOR-INITIATING CELLS
Authors: Natalie Grinshtein, Constanza Rioseco, David Uehling, Ahmed Aman, Artee Luchman, Donna Senger, Steve Robbins, Greg Cairncross, Alessandro Datti, Jeff Wrana, Steve Jones, Marco Marra, Mike Moran, Rima Al-awar, Samuel Weiss, David Kaplan
Journal: Neuro-Oncology (2015)

ATPS-28. COMBINED DRUG SCREENING AND PHOSPHOPROTEOMICS IDENTIFIES CANDIDATE BRAIN TUMOR THERAPEUTICS IN PRIMARY HUMAN BRAIN TUMOR-INITIATING CELLS Natalie Grinshtein1, Constanza Rioseco1, David Uehling2, Ahmed Aman2, Artee Luchman3, Donna Senger3, Steve Robbins3, Greg Cairncross3, Alessandro Datti4, Jeff Wrana4, Steve Jones5, Marco Marra5, Mike Moran6, Rima Al-awar2, Samuel Weiss3, and David Kaplan1,6; Hospital for Sick Children, Toronto, ON, Canada; Ontario Institute for Cancer Research, Toronto, ON, Canada; Hotchkins Brain Institute, Calgary, AB, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Genome Sciences Center, Vancouver, BC, Canada; University of Toronto, Toronto, ON, Canada  multiforme (GBM) is the most common and aggressive brain tumor with a very grim prognosis for the patients. Therapeutic Targeting of Glioblastoma is a new pan-Canadian research team of the Terry Fox Research Institute and the Canadian Stem Cell Network funded to discover efficacious therapeutics for GBM. We use our collection of over 100 primary brain tumor-initiating lines (BTICs) that are subjected to drug screening by over 1500 compounds. Multiple compounds that exhibit nanomolar cytotoxicity towards all of the BTIC lines are prioritized based upon their potency, novelty for GBM, BBB penetration and clinical status. These drugs are currently undergoing efficacy testing in an orthotopic xenograft model as single agents and in combination with TMZ. We also use phosphoproteomics as a complementary strategy to better understand BTIC signaling, identify novel targets and mechanisms of drug resistance. Phosphotyrosine characterization of 14 BTIC lines revealed heterogeneous activation of multiple RTKs in different BTIC lines, whereas non-receptor kinases were found equally phosphorylated in all BTIC lines. Moreover, we have performed phosphoproteomic analysis of 3 matching BTIC lines, tumors and xenograft samples to identify shared phospho-targets. Our results demonstrated that EGFR is the only RTK in common in matched line-tumor-xenograft samples. Other RTKs such as PDGFRA and EPH receptors, were only activated in BTIC lines, suggesting that targeting these proteins may have limited efficacy. In contrast to RTKs, multiple nonreceptor kinases were activated in matched line-tumor-xenograft samples. To validate the biological relevance of the identified shared targets, we are currently using siRNA knockdown of selected candidate proteins to assess the effect on cell viability, migration and invasion in vitro and eventually in vivo. In conclusion, we anticipate that our combined drug screening and phosphoproteomics approach will generate promising clinical candidates as well as shed light on GBM biology. Neuro-Oncology 17:v18–v40, 2015. doi:10.1093/neuonc/nov204.28 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.